Celcuity Inc
CELC
Company Profile
Business description
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
Contact
16305 36th Avenue North
Suite 100
MinneapolisMN55446
USAT: +1 763 392-0767
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
87
Stocks News & Analysis
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
We think Microsoft stock is moderately undervalued.
stocks
After earnings, is Tesla stock a buy, a sell, or fairly valued?
Q3 earnings reflected sequential improvement driven by record auto deliveries and energy storage deployments.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,178.00 | 28.70 | -0.31% |
| CAC 40 | 8,157.29 | 43.59 | -0.53% |
| DAX 40 | 24,118.89 | 5.32 | -0.02% |
| Dow JONES (US) | 47,522.12 | 109.88 | -0.23% |
| FTSE 100 | 9,760.06 | 3.92 | 0.04% |
| HKSE | 25,999.70 | 282.99 | -1.08% |
| NASDAQ | 23,581.14 | 377.33 | -1.57% |
| Nikkei 225 | 52,244.44 | 918.83 | 1.79% |
| NZX 50 Index | 13,548.32 | 89.03 | 0.66% |
| S&P 500 | 6,822.34 | 68.25 | -0.99% |
| S&P/ASX 200 | 8,881.90 | 31.30 | -0.35% |
| SSE Composite Index | 3,955.92 | 30.98 | -0.78% |